Literature DB >> 22706571

Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.

Todd A Conner1, Charles McQuade, Jonathan Olp, Amy Barton Pai.   

Abstract

Reticuloendothelial blockade in hemodialysis patients prevents optimal intravenous (IV) iron utilization. Vitamin C has emerged as a potential therapy to improve anemia treatment by enhancing iron mobilization. However, Vitamin C can act as a pro-oxidant in the presence of iron. This was a prospective, open-label, crossover study. Thirteen patients with end-stage renal disease on hemodialysis and four healthy controls were assigned to receive 100 mg of IV iron sucrose (IS) or 100 mg of IV IS co-administered with 300 mg of IV Vitamin C (IS + C) in random sequence. Serum samples for IL-1, IL-6, TNF-α and IL-10 and non-transferrin bound iron were obtained at baseline, 45 min and 105 min post study medication administration. Peripheral blood mononuclear cells were isolated at the same time points and stained with fluorescent probes to identify intracellular reactive oxygen species and mitochondrial membrane potential (Δψm) by flow cytometry. Lipid peroxidation was assessed by plasma F2-isoprosatane concentration. Both IS and IS + C were associated with increased plasma F2-isoprostanes concentrations post-infusion. Maximal plasma F2-isoprostane concentrations after IS + C were significantly elevated from baseline (234 ± 0.04 vs. 0.198 ± 0.028 ng/mL, p = 0.02). After IS + C, IL-1, IL-6, IL-10, and TNF-alpha were significantly elevated compared to baseline. After IS alone only IL-6 was noted to be elevated. Intracellular production of H(2)O(2) and loss of mitochondrial membrane potential (Δψm) was observed after IS while IS + C was associated with increased O (2) (·-) production. Both IS and IS + C induced serum cytokine activation accompanied by lipid peroxidation, however, IS + C induced higher plasma concentrations of F2-isoprostanes, IL-1, IL-10, and TNF-α post-infusion. Long-term safety studies of IV iron co-administered with Vitamin C are warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706571     DOI: 10.1007/s10534-012-9562-6

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  6 in total

1.  Evaluating plasma pharmacokinetics of intravenous iron formulations: judging books by their covers?

Authors:  Amy Barton Pai
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

2.  Prevention of renal dysfunction by nutraceuticals prepared from oil rich plant foods.

Authors:  Sahar Y Al-Okbi; Doha A Mohamed; Thanaa E Hamed; Reham Sh Esmail; Souria M Donya
Journal:  Asian Pac J Trop Biomed       Date:  2014-08

3.  Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency.

Authors:  Tanjim Sultana; Maria V DeVita; Michael F Michelis
Journal:  Int Urol Nephrol       Date:  2016-05-11       Impact factor: 2.370

4.  Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.

Authors:  Raymond D Pratt; Dorine W Swinkels; T Alp Ikizler; Ajay Gupta
Journal:  J Clin Pharmacol       Date:  2016-10-03       Impact factor: 3.126

Review 5.  Role of Vitamin C in Skin Diseases.

Authors:  Kaiqin Wang; Hui Jiang; Wenshuang Li; Mingyue Qiang; Tianxiang Dong; Hongbin Li
Journal:  Front Physiol       Date:  2018-07-04       Impact factor: 4.566

Review 6.  Two Faces of Vitamin C in Hemodialysis Patients: Relation to Oxidative Stress and Inflammation.

Authors:  Patrick Chaghouri; Nour Maalouf; Sophia Lorina Peters; Piotr Jan Nowak; Katarzyna Peczek; Anna Zasowska-Nowak; Michal Nowicki
Journal:  Nutrients       Date:  2021-02-27       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.